MedTrace Logo

Antiviral Activity of AZD7295 in HCV Carriers

NCT00781976 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2010-03-31

No results posted yet for this study

Summary

PK, safety study of AZD7295 in HCV carriers

Conditions

  • Hepatitis C

Interventions

DRUG

AZD7295

700mg per day maximum

DRUG

Placebo

matched placebo

Sponsors & Collaborators

  • Arrow Therapeutics

    lead INDUSTRY

Principal Investigators

  • Ed Gane · Auckland Clinical Services

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2010-03-31
Completion
2010-03-31

Countries

  • New Zealand

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00781976 on ClinicalTrials.gov